Medicenna Therapeutics Corp
Research Medicenna Therapeutics Corp (MDNA) on Bullrun: market cap CAD 37.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDNA
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 37.84M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 4.23M
- Free cash flow-CAD 4.48M
Valuation Snapshot
latest market cap is CAD 37.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 12.99M | -CAD 18.44M | n/a | n/a | CAD 10.61M | CAD 135.00K | CAD 6.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 37.84M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medicenna Therapeutics Corp's market cap?
Medicenna Therapeutics Corp's market capitalization is CAD 37.84M.
What does Medicenna Therapeutics Corp do?
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer.